ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials

X. Wang,1 J. Chen,2 X. Tu,2 Y. Qiu,1 T. Song,1 T. Lin.1

1Department of Urology/Institute of Urology/Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
2West China School of Clinical Medicine, Sichuan University, Chengdu, Sichuan Province, China.

Meeting: 2018 American Transplant Congress

Abstract number: B130

Keywords: Induction therapy, Kidney transplantation, Meta-analysis, Rejection

Session Information

Date: Sunday, June 3, 2018

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Related Abstracts
  • A Meta-Analysis for Induction Therapy of Kidney Transplantation: Comparison of Antithymocyte Globulin and Interleukin 2 Receptor Antagonist
  • Current Treatments for Small Hepatocellular Carcinoma: A Network Meta-Analysis of Randomized Controlled Trials.

Objectives. This meta-analysis was undertaken to assess the efficacy and safety of rituximab as induction therapy in kidney transplantation.

Methods. OVID, Embase, SCI, PubMed and EBSCO were searched till May 2016 to identify randomized controlled trials (RCTs) that used rituximab as induction therapy in kidney transplantation. Major outcomes included rejection, infection, graft survival, and death. The meta-analysis was performed using Review Manager 5.3.5.

Results. Five RCTs met our selection criteria, including 482 kidney transplant recipients. Four of them were multicenter studies. The patients sample size ranged from 13 to 280 and the follow-up duration from 1 to 3 years. The meta-analysis showed that rituximab induction significantly reduced antibody-mediated rejections (2.9% vs. 9.7%; RR =0.32; 95%CI 0.13-0.76; P=0.01). No significant differences were observed in other efficacy and safety parameters: acute rejection (16.8% vs. 21.1%; RR=0.80; 95%CI 0.55-1.17; P=0.25), graft survival (94.8% vs. 90.7%; RR=1.05; 95%CI 0.99-1.10; P=0.09), mortality (2.6% vs. 3.0%; RR=0.87; 95%CI 0.32-2.37; P=0.79) and cytomegalovirus infection (12.8% vs. 10.0%; RR=1.29; 95%CI 0.78-2.12; P=0.33), respectively.

Conclusions. It is safe to use rituximab as induction therapy in kidney transplantation, and rituximab induction could significantly reduce antibody-mediated rejection.

CITATION INFORMATION: Wang X., Chen J., Tu X., Qiu Y., Song T., Lin T. The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wang X, Chen J, Tu X, Qiu Y, Song T, Lin T. The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials [abstract]. https://atcmeetingabstracts.com/abstract/the-efficacy-and-safety-of-rituximab-as-induction-therapy-in-kidney-transplantation-a-meta-analysis-of-randomized-controlled-trials/. Accessed February 28, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.